The Accenture Life Sciences practice helps companies pivot to the patient for best outcomes. See how we can help you. Visit https://accntu.re/2l5mUGu to learn more.
Accenture's Technology Vision 2021 details emerging technology trends that will help companies get back on track & build their future post COVID-19. Read more.
The Accenture Life Sciences practice helps companies pivot to the patient for best outcomes. See how we can help you. Visit https://accntu.re/2l5mUGu to learn more.
Accenture's Technology Vision 2021 details emerging technology trends that will help companies get back on track & build their future post COVID-19. Read more.
Accenture Digital Health Technology Vision 2018accenture
Explore Accenture's Digital Health Tech Vision 2018 report, showcasing five health IT trends that are going to redefine how intelligent enterprises of the future will work. Learn more: https://accntu.re/2IoOLMI
Engineering Services: con gli ingegneri per creare valore sostenibileaccenture
Collaboriamo con gli ingegneri di aziende capital intensive per combinare tecnologie innovative con un approccio pragmatico che aiuti a raggiungere risultati aziendali migliori.
MPG Life Sciences Software Market Snapshot October 2020Madison Park Group
We are pleased to present our life sciences software market snapshot for October 2020.
Madison Park Group is a unique investment banking firm that takes a "strategy first" approach to advising software companies. Our partners have developed and advised numerous successful companies as operators, investors and investment bankers.
Rohan Khanna, Jonathan Adler and James Tomasullo spearhead the firm's efforts in the space.
Accenture Digital Health Technology Vision 2018accenture
Explore Accenture's Digital Health Tech Vision 2018 report, showcasing five health IT trends that are going to redefine how intelligent enterprises of the future will work. Learn more: https://accntu.re/2IoOLMI
Engineering Services: con gli ingegneri per creare valore sostenibileaccenture
Collaboriamo con gli ingegneri di aziende capital intensive per combinare tecnologie innovative con un approccio pragmatico che aiuti a raggiungere risultati aziendali migliori.
MPG Life Sciences Software Market Snapshot October 2020Madison Park Group
We are pleased to present our life sciences software market snapshot for October 2020.
Madison Park Group is a unique investment banking firm that takes a "strategy first" approach to advising software companies. Our partners have developed and advised numerous successful companies as operators, investors and investment bankers.
Rohan Khanna, Jonathan Adler and James Tomasullo spearhead the firm's efforts in the space.
The Work Ahead in Life Sciences: Cures at the Speed of DigitalCognizant
Life sciences businesses have accelerated their digital-first journey to operate in a world where time-to-everything matters more than any other strategic imperative, according to our study.
How life sciences can win with blockchainToni Borges
The IBM Institute for Business Value surveyed 205 life sciences executives in 18 countries. The study, conducted in collaboration with the Economist Intelligence Unit (EIU), included chief financial officers (CFOs), chief technology officers (CTOs) and chief information officers (CIOs). Those participating had to meet specific criteria: they were either working with — or planning to work with — blockchains in the next 12 months, and they needed to be familiar with the blockchain strategies of their organizations.
The FDA Digital Health Center of Excellence and the Advancement of Digital He...Greenlight Guru
The FDA Digital Health Center of Excellence is part of the planned evolution of the digital health program with the intent to drive synergy for digital health efforts, align strategy with implementation, prepare the FDA for the digital health future, and protect patients and maintain the FDA standards of safety and effectiveness.
Ultimately, the program works to strategically advance science and evidence for digital health technologies that meets the needs of
stakeholders.
This free in-depth webinar, presented by Matthew DiamondChief Medical Officer, Digital Health Center of Excellence, will cover the digital health landscape and areas of application, goals and outcomes, planned services and launch plan, and the current areas of focus - including AI/ML-Based SaMD.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
Why is Pharmacovigilance required in pharmaceutical markets for all countries? Majorly it is due to adverse drug reactions (ADR) that lead to severe illness, permanent side effects, and even death.
Data-driven Healthcare for ManufacturersLindaWatson19
Medical Device Equipment and Hospital Supplies Manufacturers also face increased pressure to comply with strict regulatory procedures to ensure patient safety. Product transparency and efficient end-to-end processes that optimize the manufacturing process and decision making are very important.
Data-Driven Healthcare for Manufacturers Amit Mishra
Data-driven healthcare empowers the providers with a common data platform to discover untapped data-driven opportunities. Healthcare data and its impact on the patient care decision process via accurate, real-time, reliable data from disparate sources is creating a digital health revolution. Physician groups, nursing facilities, hospitals, pharmaceutical companies, clinical researchers, and medical equipment manufacturers are all churning out vast amounts of data during their daily operations. This data has tremendous value and can revolutionize patient care, diagnosis, real-time decisions and help deliver new, unimagined innovations with quality of patient care. Know more about data-driven healthcare at https://www.solix.com/solutions/data-driven-solutions/healthcare/
One of the hottest topics in the biopharmaceutical industry today is “continuous bioprocessing”. Buzzwords such as “process intensification”, “next generation bioprocessing”, “process optimization”, and “integrated, connected manufacturing” are prevalent in industry conference programs and biopharma trade publications. This is no surprise considering that by 2025, it is expected that 20 percent of revenue from molecules that are still in the pipeline today will come from drugs manufactured with next generation technologies. It is estimated that roughly 35 percent of today’s commercial molecules will utilize process intensification methods within the next 5-10 years.
But what actually is next generation bioprocessing? How are industry players defining next generation bioprocessing and how will they pursue and successfully implement this approach? And is continuous bioprocessing always the ultimate end goal drug manufacturers around the globe are, or should be, striving for?
In this dedicated supplement, experts from both biologics manufacturers and from Merck provide their insights and perspectives on the on-going paradigm shift towards next generation bioprocessing occurring in today’s and tomorrow’s biopharma landscape.
Development and Co-Commercialization for Emerging Biotech organizationsIndegene
Develop, launch and market your product with an experienced partner. Innovative, technology-led, purpose-built, end-to-end and individual development and commercialization solutions from Phase 2 clinical trials to Loss Of Exclusivity (LOE) for a more effective, sustained, and higher peak revenue.
Integration of Clinical Trial Systems: Enhancing Collaboration and EfficiencyClinosolIndia
Clinical trials are complex endeavors that involve numerous stakeholders, vast datasets, and intricate processes. To streamline operations, enhance collaboration, and improve efficiency, the integration of clinical trial systems has emerged as a pivotal solution. This strategic approach involves connecting various components, such as electronic data capture (EDC) systems, clinical trial management systems (CTMS), and electronic health records (EHR), fostering a cohesive ecosystem that accelerates the pace of research and ensures data accuracy.
PharmaLedger Press Release #2 June 2020 PharmaLedger
PharmaLedgers June 2020 press release covers the strong foundations in the project’s first year and how it set the stage for accelerated development and ecosystem engagement.
The press release also announces the establishment of PharmaLedger’s Advisory Board and the outlook for 2021.
—
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Digital Transformation of Healthcare amid COVID-19 Pandemic.pdfShelly Megan
The COVID-19 pandemic led to the digitalization of the healthcare sector, primarily influencing the remote working capabilities and user experience. Digitalization of healthcare fastened the diagnosis, enabling faster and better treatment. Tele medicine has proved to be very beneficial. The digital supply chain management solution is another significant advancement. These digital advancements will have a long-term impact on the healthcare system, boosting the user experience and affordability.
How AI and Machine Learning can improve patient access to orphan drugs.pptxVidyaBreeveldDwarkas
On March 22 2022 I held this thought provoking presentation about the use of modern information technologies to aid patient access to orphan drugs at the World EPA congress in Amsterdam.
My conclusion: These technologies could be valuable instruments that help to provide solutions to fill the data gaps in health technology assessments and guide policy decisions. However, since there are many actors involved, to improve patient access to orphan drugs an ecosystem innovation is needed. Unless this is addressed, these modern technologies will not provide solutions that benefit patient access.
Our central thesis has long been that COVID hasn’t dramatically changed the healthcare industry, rather it has dramatically accelerated different trends in the healthcare space that were already simmering before March 2020. Given the usually slow pace at which the healthcare market typically moves, COVID served as a shock to the system and an accelerator that created a window to drive meaningful change. In this whitepaper, we will examine several changes that were less obvious in the early days of the pandemic and assess their longevity as we (hopefully) move into a post-COVID world.
Overview of Technology Transfer in Pharmaceutical Industryijtsrd
This essay discusses technology transfer, its uses, and how important they are to the finding of new drugs and the creation of new pharmaceuticals. Additionally, it is necessary to improve the drug quality intended during research and development, to the finished product during production, and to ensure that consistent quality is needed. This research aimed to examine the significance of technology transfer, its components, and manufacturing unit technology transfer policies. The shift contributes to the technical advancement of succeeding companies through RandD and startup companies. A. Ezhilarasi | Dr. K. Devi | Shantaram Nangude "Overview of Technology Transfer in Pharmaceutical Industry" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-7 | Issue-2 , April 2023, URL: https://www.ijtsrd.com.com/papers/ijtsrd54023.pdf Paper URL: https://www.ijtsrd.com.com/pharmacy/other/54023/overview-of-technology-transfer-in-pharmaceutical-industry/a-ezhilarasi
Similar to The Digital Thread for Life Sciences | Accenture (20)
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...UiPathCommunity
💥 Speed, accuracy, and scaling – discover the superpowers of GenAI in action with UiPath Document Understanding and Communications Mining™:
See how to accelerate model training and optimize model performance with active learning
Learn about the latest enhancements to out-of-the-box document processing – with little to no training required
Get an exclusive demo of the new family of UiPath LLMs – GenAI models specialized for processing different types of documents and messages
This is a hands-on session specifically designed for automation developers and AI enthusiasts seeking to enhance their knowledge in leveraging the latest intelligent document processing capabilities offered by UiPath.
Speakers:
👨🏫 Andras Palfi, Senior Product Manager, UiPath
👩🏫 Lenka Dulovicova, Product Program Manager, UiPath
DevOps and Testing slides at DASA ConnectKari Kakkonen
My and Rik Marselis slides at 30.5.2024 DASA Connect conference. We discuss about what is testing, then what is agile testing and finally what is Testing in DevOps. Finally we had lovely workshop with the participants trying to find out different ways to think about quality and testing in different parts of the DevOps infinity loop.
Essentials of Automations: Optimizing FME Workflows with ParametersSafe Software
Are you looking to streamline your workflows and boost your projects’ efficiency? Do you find yourself searching for ways to add flexibility and control over your FME workflows? If so, you’re in the right place.
Join us for an insightful dive into the world of FME parameters, a critical element in optimizing workflow efficiency. This webinar marks the beginning of our three-part “Essentials of Automation” series. This first webinar is designed to equip you with the knowledge and skills to utilize parameters effectively: enhancing the flexibility, maintainability, and user control of your FME projects.
Here’s what you’ll gain:
- Essentials of FME Parameters: Understand the pivotal role of parameters, including Reader/Writer, Transformer, User, and FME Flow categories. Discover how they are the key to unlocking automation and optimization within your workflows.
- Practical Applications in FME Form: Delve into key user parameter types including choice, connections, and file URLs. Allow users to control how a workflow runs, making your workflows more reusable. Learn to import values and deliver the best user experience for your workflows while enhancing accuracy.
- Optimization Strategies in FME Flow: Explore the creation and strategic deployment of parameters in FME Flow, including the use of deployment and geometry parameters, to maximize workflow efficiency.
- Pro Tips for Success: Gain insights on parameterizing connections and leveraging new features like Conditional Visibility for clarity and simplicity.
We’ll wrap up with a glimpse into future webinars, followed by a Q&A session to address your specific questions surrounding this topic.
Don’t miss this opportunity to elevate your FME expertise and drive your projects to new heights of efficiency.
GraphRAG is All You need? LLM & Knowledge GraphGuy Korland
Guy Korland, CEO and Co-founder of FalkorDB, will review two articles on the integration of language models with knowledge graphs.
1. Unifying Large Language Models and Knowledge Graphs: A Roadmap.
https://arxiv.org/abs/2306.08302
2. Microsoft Research's GraphRAG paper and a review paper on various uses of knowledge graphs:
https://www.microsoft.com/en-us/research/blog/graphrag-unlocking-llm-discovery-on-narrative-private-data/
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...James Anderson
Effective Application Security in Software Delivery lifecycle using Deployment Firewall and DBOM
The modern software delivery process (or the CI/CD process) includes many tools, distributed teams, open-source code, and cloud platforms. Constant focus on speed to release software to market, along with the traditional slow and manual security checks has caused gaps in continuous security as an important piece in the software supply chain. Today organizations feel more susceptible to external and internal cyber threats due to the vast attack surface in their applications supply chain and the lack of end-to-end governance and risk management.
The software team must secure its software delivery process to avoid vulnerability and security breaches. This needs to be achieved with existing tool chains and without extensive rework of the delivery processes. This talk will present strategies and techniques for providing visibility into the true risk of the existing vulnerabilities, preventing the introduction of security issues in the software, resolving vulnerabilities in production environments quickly, and capturing the deployment bill of materials (DBOM).
Speakers:
Bob Boule
Robert Boule is a technology enthusiast with PASSION for technology and making things work along with a knack for helping others understand how things work. He comes with around 20 years of solution engineering experience in application security, software continuous delivery, and SaaS platforms. He is known for his dynamic presentations in CI/CD and application security integrated in software delivery lifecycle.
Gopinath Rebala
Gopinath Rebala is the CTO of OpsMx, where he has overall responsibility for the machine learning and data processing architectures for Secure Software Delivery. Gopi also has a strong connection with our customers, leading design and architecture for strategic implementations. Gopi is a frequent speaker and well-known leader in continuous delivery and integrating security into software delivery.
UiPath Test Automation using UiPath Test Suite series, part 3DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 3. In this session, we will cover desktop automation along with UI automation.
Topics covered:
UI automation Introduction,
UI automation Sample
Desktop automation flow
Pradeep Chinnala, Senior Consultant Automation Developer @WonderBotz and UiPath MVP
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024Tobias Schneck
As AI technology is pushing into IT I was wondering myself, as an “infrastructure container kubernetes guy”, how get this fancy AI technology get managed from an infrastructure operational view? Is it possible to apply our lovely cloud native principals as well? What benefit’s both technologies could bring to each other?
Let me take this questions and provide you a short journey through existing deployment models and use cases for AI software. On practical examples, we discuss what cloud/on-premise strategy we may need for applying it to our own infrastructure to get it to work from an enterprise perspective. I want to give an overview about infrastructure requirements and technologies, what could be beneficial or limiting your AI use cases in an enterprise environment. An interactive Demo will give you some insides, what approaches I got already working for real.
UiPath Test Automation using UiPath Test Suite series, part 4DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 4. In this session, we will cover Test Manager overview along with SAP heatmap.
The UiPath Test Manager overview with SAP heatmap webinar offers a concise yet comprehensive exploration of the role of a Test Manager within SAP environments, coupled with the utilization of heatmaps for effective testing strategies.
Participants will gain insights into the responsibilities, challenges, and best practices associated with test management in SAP projects. Additionally, the webinar delves into the significance of heatmaps as a visual aid for identifying testing priorities, areas of risk, and resource allocation within SAP landscapes. Through this session, attendees can expect to enhance their understanding of test management principles while learning practical approaches to optimize testing processes in SAP environments using heatmap visualization techniques
What will you get from this session?
1. Insights into SAP testing best practices
2. Heatmap utilization for testing
3. Optimization of testing processes
4. Demo
Topics covered:
Execution from the test manager
Orchestrator execution result
Defect reporting
SAP heatmap example with demo
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Transcript: Selling digital books in 2024: Insights from industry leaders - T...BookNet Canada
The publishing industry has been selling digital audiobooks and ebooks for over a decade and has found its groove. What’s changed? What has stayed the same? Where do we go from here? Join a group of leading sales peers from across the industry for a conversation about the lessons learned since the popularization of digital books, best practices, digital book supply chain management, and more.
Link to video recording: https://bnctechforum.ca/sessions/selling-digital-books-in-2024-insights-from-industry-leaders/
Presented by BookNet Canada on May 28, 2024, with support from the Department of Canadian Heritage.
Accelerate your Kubernetes clusters with Varnish CachingThijs Feryn
A presentation about the usage and availability of Varnish on Kubernetes. This talk explores the capabilities of Varnish caching and shows how to use the Varnish Helm chart to deploy it to Kubernetes.
This presentation was delivered at K8SUG Singapore. See https://feryn.eu/presentations/accelerate-your-kubernetes-clusters-with-varnish-caching-k8sug-singapore-28-2024 for more details.
Key Trends Shaping the Future of Infrastructure.pdfCheryl Hung
Keynote at DIGIT West Expo, Glasgow on 29 May 2024.
Cheryl Hung, ochery.com
Sr Director, Infrastructure Ecosystem, Arm.
The key trends across hardware, cloud and open-source; exploring how these areas are likely to mature and develop over the short and long-term, and then considering how organisations can position themselves to adapt and thrive.
2. Setting a new pace of change
The lessons of the last
year can help power the
discovery, development
and delivery of new
treatments for all health
conditions.
• Phase II and III protocol procedures have
increased 44% since 2009,
• Patient stratification and novel
biomarkers/endpoints driving a rise in trial
complexity.
More treatments
in development
+ market
stratification
• AI-based methodologies reduce time spent for
discovery from 4.5 years to a year.
• Virtual clinical trials grew by over 50%
in 2020.
• Average treatment duration of decentralized
trials was 36% (140 days) faster
Treatments are
coming to market
faster than ever
• Driving 81% of biopharma revenue growth and
61% of all revenues (2021-2026).
• The average NPV of New Science treatments to
be launched from 2022-2026 will exceed
traditional counterparts by 69%.
New Science
is more important
than ever
3. COVID-19 highlighted many orthodoxies
within life sciences that have now been
dispelled
Orthodoxy 1
We can’t change the
way we discover
medicine
Orthodoxy 2
We can’t deviate from
in-person clinical
trials, at premier sites
Orthodoxy 3
We can’t rapidly scale
manufacturing for new
modalities
4. What if we could…
Accelerate
early process
development
Accelerate filing
and approval of the
CMC dossier
Execute flawless
tech transfer of
manufacturing process
between teams
Optimize and speed
the manufacturing
process
6. Putting the digital thread in life sciences
(DTLS) to use
A biopharma client with one of the
most exciting pipelines in the
industry.
Looking to create a digital bridge
between R&D through
manufacturing to enhance new
product launch capability.
New product introduction and
technology transfer is historically
paper driven, time and effort
intensive and error prone.
This creates risk of delays in
product launch and ripple effects
in wider portfolio.
Leveraged and enhanced existing
IT platforms to create a digital
product profile and digitization of
the manufacturing control
strategy.
Initial pilot on a biologic tech
transfer resulted in more than 20%
reduction in effort.
The
opportunity
The typical
challenges
The DTLS
outcome
7. Migrate and
free-up
resources
Accelerating the digital thread with cloud
Adopt modern
application
development
practices
Gain faster,
deeper insights
with analytics
Ensure security,
compliance
and resiliency
Organize for
speed and agility
Bridge skills
and experience
gaps rapidly
8. Technical
Outcomes
Creating end-to-end integration with DTLS
Rapid drug discovery and
accelerated clinical
development
Smart factories for small
and large molecule drugs
Holistic view
of data
Interconnected
global network
Lifesaving treatments
reach more patients
Rapidly scale up manufacturing to support new clinical
and commercial launches
Quickly evaluate manufacturing feasibility with rapid feedback to
development cycle
Create end-to-end visibility by integrating operational manufacturing
information from disparate systems
Seamlessly bring data together across data lakes and source
systems to enable additional processing or transfer of information